NCT00993681CompletedPhase 3
A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System
Intercell USA, Inc.20 sites in 4 countries2,036 target enrollmentStarted: October 1, 2009Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Intercell USA, Inc.
- Enrollment
- 2,036
- Locations
- 20
- Primary Endpoint
- Incidence of cases with vaccine preventable outcome
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy of the Travelers' Diarrhea Vaccine System to actively immunize against Enterotoxigenic Escherichia coli disease in a field setting.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 64 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •18-64 years of age at date of first vaccination
- •Good health as determined by medical history and physical inspection
- •Females of child-bearing potential must have a negative pregnancy test prior to first vaccination in teh Country of Origin; females of child-bearing potential must agree not to become pregnant throughout the duration of the study
- •Subjects must have planned travel to an area within 3 hours traveling distance of Mexico City, Cuernavaca, Guadalajara, Oaxaca, or San Miguel de Allende, Mexico or Antigua, Quezaltenango, Guatemala City, or Solola, Guatemala for a minimum duration of stay 7 days (no maximum stay is specified for inclusion).
- •Subject must be able to communicate in English
Exclusion Criteria
- •Abnormalities as determined by the Investigator/clinician during physical inspection
- •Participated in research involving investigational product within 30 days before planned date of first vaccination
- •Ever received LT, ETEC, or cholera vaccine
- •History of diarrhea while traveling to a developing country within the last year
- •Women who are pregnant or breastfeeding
- •Clinically significant underlying enteric, pulmonary, cardiac, liver or renal disease
- •History of Irritable Bowel Syndrome
- •Seizure disorder within the last year
- •Current use of immunosuppressive therapy (excluding inhaled steroids) or current immunodeficiency
- •Known or suspected alcohol abuse or illicit drug use within the last year
- •Medical history of HIV, HBV, or HCV
- •An employee of a study site
- •Known allergies to any component of the vaccine, including adhesives
- •Planned use of antibiotics with known activity against gram negative facultative anaerobes
- •Planned use of antacids, antidiarrheals, loperamide, bismuth subsalicylate, diphenoxylate or similar during the surveillance phase of the study
- •An employee of Intercell (global) or an immediate family member
Arms & Interventions
1
Experimental
900 subjects will receive a two vaccination regimen with an LT patch
Intervention: TD Vaccine System (Biological)
2
Placebo Comparator
900 subjects will receive a two vaccination regimen with a placebo patch
Intervention: TD Vaccine System (Biological)
Outcomes
Primary Outcomes
Incidence of cases with vaccine preventable outcome
Time Frame: Day 17 (17 days after arrival in destination country)
Secondary Outcomes
- The incidence of moderate/severe diarrhea(Day 17 (17 days after arrival in destination country))
- Total unformed stool frequency from diarrheal episodes(Day 17 (17 days after arrival in destination country))
- Total duration of diarrheal episodes(Day 17 (17 days after arrival in destination country))
Investigators
Study Sites (20)
Loading locations...
Similar Trials
Completed
Phase 2
Traveler's Diarrhea (TD) Vaccine Asia Efficacy StudyTraveler's DiarrheaNCT01040325Intercell USA, Inc.723
Completed
Phase 3
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy ChildrenHealthy VolunteersNCT02747927Takeda20,099
Completed
Phase 3
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsMeningococcal MeningitisTyphoidJapanese EncephalitisMeningococcal DiseaseYellow FeverRabiesNCT01466387Novartis552
Completed
Phase 3
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13Pneumococcal DiseaseNCT05408429Pfizer356
Completed
Phase 1
Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B InfectionChronic Hepatitis BNCT00277576PowderMed48